What Is The Current and Historic Market Size Analysis Of The VELETRI Market?
The veletri market has seen considerable growth due to a variety of factors.
• The market scale of VELETRI has seen substantial growth in the past few years. Its projected growth is from $1.34 billion in 2024 to $1.45 billion in 2025, with a compound annual growth rate (CAGR) of 7.9%.
The historical growth spikes are linked to the escalating prevalence of pulmonary arterial hypertension (PAH), increasing consciousness about PAH, a ballooning elderly population, a global rise traced back to alterations in lifestyle, and heightened healthcare spending.
What Is The Forecast For The VELETRI Market Size?
The veletri market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for a sturdy upturn in the VELETRI market size within the forthcoming years. By 2029, the market's growth is anticipated to reach $1.95 billion, augmenting at a compound annual growth rate (CAGR) of 7.7%.
The factors contributing to this predicted expansion during the forecast period include an increased incidence of venous diseases, a rise in early diagnosis due to greater awareness, increased expenditure on chronic diseases, enhanced healthcare infrastructure, and an expanding patient base. The forecast period is also likely to see significant trends such as technological progression, partnerships between pharmaceutical firms and research institutes, a strong clinical research pipeline, increased R&D activities, as well as the introduction of biosimilars and generics.
What Are The Essential Drivers Behind The Growth Of The VELETRI Market?
The VELETRI market's growth is projected to be spurred by the escalating occurrence of pulmonary arterial hypertension (PAH). PAH is a unique, progressively worsening condition marked by elevated blood pressure in the lung arteries, potentially leading to heart failure if not managed. This upsurge in PAH prevalence is linked to factors such as better diagnostic methods, an aging demographic, and heightened awareness of the disease. Veletri aids in the treatment of PAH by enhancing physical ability and decelerating disease development via vasodilation. For instance, the American College of Cardiology Foundation, a non-profit medical organization based in the United States, stated in October 2022 that PAH is a rare disease affecting about 15 to 30 individuals per million. Hence, the increasing occurrence of PAH is fueling the expansion of the VELETRI market. A surge in venous disease prevalence is anticipated to boost the growth of the VELETRI market. Venous diseases, characterized by reduced blood circulation in the veins, result in swelling, discomfort, and potential complications such as varicose veins and deep vein thrombosis. This increase in venous diseases can be attributed to factors like an aging population, sedentary lifestyles, obesity, and enhanced diagnostic capabilities. Veletri helps to elevate exercise performance and minimize symptoms in patients with venous diseases impacting the pulmonary vasculature. For instance, the Centers for Disease Control and Prevention reported in January 2025 that each year, up to 900,000 people in the United States suffer from venous thromboembolism, a condition characterized by blood clots, with an estimated 60,000 to 100,000 deaths annually attributed to VTE. Hence, increasing venous disease occurrence is pushing the VELETRI market's expansion.
How Is The Global VELETRI Market Divided Into Key Segments?
The veletri market covered in this report is segmented –
1) By Product Type: Injectable, Inhalation
2) By Application: Pulmonary Arterial Hypertension, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Injectable: Intravenous (IV) Injection, Subcutaneous (SC) Injection
2) By Inhalation: Nebulized Inhalation, Dry Powder Inhalation
Pre-Book The VELETRI Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Who Are the Key Players In The VELETRI Market?
Major companies operating in the veletri market are:
• Johnson & Johnson
• Bayer Pharma AG
• Novartis AG
• GlaxoSmithKline plc
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Sandoz International GmbH
• Sun Pharmaceutical Industries Ltd.
• Actelion Pharmaceuticals Ltd.
• Euroapi S.A.
• United Therapeutics Corporation
• Pfizer CentreOne
• Sai Life Sciences Limited
• Zhejiang Ausun Pharmaceutical Co. Ltd.
• Yonsung Fine Chemicals Co. Ltd.
• Cayman Pharma S.r.o.
• Meitheal Pharmaceuticals Inc.
• Smiths Medical
• Guangzhou Tosun Pharmaceutical Co. Ltd.
What Are The Regional Insights Into The VELETRI Market?
North America was the largest region in the VELETRI market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veletri market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
